Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes
Journal of the American Academy of Dermatology Jan 05, 2022
Gupta N, Weitzman RE, Murad F, et al. - Findings demonstrate an 8% likelihood of developing poor outcomes in BWH (Brigham and Women's Hospital) T2a-high cutaneous squamous cell carcinomas (CSCCs).
In this 17-year retrospective multi-institutional cohort study, a predictive model based on tumor characteristics was constructed to unveil risk factors related to poor outcomes (nodal metastasis, distant metastases, and disease-specific deaths) in BWH T2a CSCC.
Poor outcomes were best predicted by the presence of 1 major criterion (primary tumor diameter ≥40 mm, invasion depth beyond subcutaneous fat, poor differentiation, or large-caliber perineural invasion) and ≥ 1 minor criterion (invasion depth in subcutaneous fat, moderate differentiation, small-caliber perineural invasion, or lymphovascular invasion).
The sensitivity, specificity, positive and negative predictive values yielded by the model were 7.7%, 97.4%, 33.3% and 86.1%, respectively.
In these tumors, 5-year cumulative incidence of poor outcomes was estimated to be 8.0% (95% CI, 5.1-13.7) vs 2.8% (95% CI, 1.9-4.1) in other T2a tumors (sub-hazard ratio, 3.0; 95% CI, 1.5-5.8).
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries